The first-of-its-kind facility in India has received an investment of $75 million from the company to build it vertically ...

A collaborative study led by Prof. Liu Guanghui from the Institute of Zoology of the Chinese Academy of Sciences and Dr. Wang ...

Oxford, UK - 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today ...

Edinburgh-based biotech company Lentitek Ltd has secured £700,000 in private funding from Equity Gap, a leading Scottish angel investment syndicate, bringing its total investment to £1 million in the ...

Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...

Immunotherapy has emerged as one of the major options for cancer treatment in the past decade. With the successful application of immune checkpoint inhibitors and the introduction of immune regulatory ...

Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...